Our Resources | Association for Accessible Medicines

AAM President & CEO John Murphy III at GRx+Biosims 2024

Nov 8, 2024 | Jennifer Soup

GRx+Biosims 2024 Conference Recap

American Flag in front of The White House in Washington D.C.

Nov 7, 2024 | AAM

AAM & Biosimilars Council Statement on Presidential Election

Oct 16, 2024 | AAM

$2 Generics List Not the Solution

Sep 25, 2024 | AAM

John Murphy Named President and CEO of AAM

congress building

Sep 24, 2024 | Comms Temp

AAM Urges Congress to Pass Key Bills Considered by the Senate HELP Committee This Week

Hatch-Waxman Turns 40

Sep 24, 2024 | AAM

40 Years of Hatch-Waxman – Trillions in Savings for Patients

Scientists in lab

Sep 18, 2024 | AAM

Generic Medicines Increase Patient Access More Than Government Negotiated Price Controls

Sep 13, 2024 | AAM

Statement Regarding Senate Judiciary Committee Markup of the PREVAIL Act and the PERA Act

Sep 10, 2024 | AAM

Want to Save Patients Money on Medicine? No Need to Reinvent the Wheel

Sep 10, 2024 | AAM

AAM and the Biosimilar Council Host Patent Abuse Congressional Briefing: What’s Truly Preventing Low-Cost Medicines from Getting to Patients: A Look at the Broken Patent System

AAM Amicus Brief

Sep 6, 2024 | AAM

Amarin v. Hikma

2024 U.S. Generic and Biosimilar Medicines Savings Report

Sep 5, 2024 | AAM

Generic and Biosimilar Medicines Save $445 Billion in 2023